title: Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease.
abstract: BACKGROUND
  Matrix metalloproteinase (MMP)-9 is thought to be involved in coronary artery aneurysms (CAAs) in patients with Kawasaki disease (KD); however, MMP-9 inhibitors are not used clinically. This study investigated whether the angiotensin-converting enzyme (ACE) inhibitor captopril could inhibit serum MMP-9 activity using serum from KD patients in an in vitro experiment.
  
  
  METHODS
  In 7 KD patients, serum MMP-9 activity was measured using the MMP-9 assay kit 3 times: before and after intravenous immunoglobulin (IVIG) treatment, and during the convalescent phase. The effect of captopril on MMP-9 activity was also assessed using serum obtained before IVIG treatment.
  
  
  RESULTS
  Serum MMP-9 activity was significantly higher during the pre-treatment phase than during the post-treatment and convalescent phases. MMP-9 activity during the pre-treatment phase was dose-dependently inhibited by captopril, and the IC(50) for MMP-9 was 500nM. The potency of captopril for MMP-9 inhibition was comparable to that for ACE inhibition.
  
  
  CONCLUSIONS
  ACE inhibitor may be effective for preventing CAA formation in KD patients, especially IVIG non-responders.
authors: Department of Pharmacology, Osaka Medical College, Takatsuki 569-8686, Japan.
authors: Nao
authors: N
authors: Inoue
authors: Shinji
authors: S
authors: Takai
authors: Denan
authors: D
authors: Jin
authors: Kenichi
authors: K
authors: Okumura
authors: Naoyuki
authors: N
authors: Okamura
authors: Mitsugu
authors: M
authors: Kajiura
authors: Sosuke
authors: S
authors: Yoshikawa
authors: Naohisa
authors: N
authors: Kawamura
authors: Hiroshi
authors: H
authors: Tamai
authors: Mizuo
authors: M
authors: Miyazaki
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D002216:Captopril / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D061965:Matrix Metalloproteinase Inhibitors; D009080:Mucocutaneous Lymph Node Syndrome / Q000097:blood / Q000201:enzymology*; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D002216:Captopril; D007703:Peptidyl-Dipeptidase A; D020780:Matrix Metalloproteinase 9